Sangamo Acquisition Of Edwards’ R&D Program Will Enhance Partnering Opportunities
This article was originally published in The Pink Sheet Daily
Sangamo will acquire Edwards’ angiogenesis program based on zinc finger protein activation of the VEGF gene.
You may also be interested in...
Genentech and Medarex are the only two firms with commercial licenses for the zinc finger DNA-binding protein technology.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.